Scarica l'app Stockscreener
3.55
10.25%
0.33
Precedente Chiudi:
$3.22
Aprire:
$3.3
Volume 24 ore:
3.10M
Relative Volume:
0.75
Capitalizzazione di mercato:
$477.74M
Reddito:
-
Utile/perdita netta:
$-217.44M
Rapporto P/E:
-1.6359
EPS:
-2.17
Flusso di cassa netto:
$-205.20M
1 W Prestazione:
-0.56%
1M Prestazione:
-21.63%
6M Prestazione:
+19.73%
1 anno Prestazione:
-14.25%
Intervallo 1D:
$3.2401
$3.64
Intervallo di 1 settimana:
$3.0846
$3.70
Portata 52W:
$1.11
$5.17
Prime Medicine Inc Stock (PRME) Company Profile
Nome
Prime Medicine Inc
Settore
Industria
Telefono
617-465-0013
Indirizzo
60 FIRST ST., CAMBRIDGE
Confronta PRME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.55 | 623.96M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-22 | Iniziato | Chardan Capital Markets | Buy |
| 2024-04-08 | Iniziato | TD Cowen | Buy |
| 2024-04-03 | Iniziato | Wedbush | Outperform |
| 2024-01-16 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Iniziato | Citigroup | Neutral |
| 2023-10-09 | Iniziato | BMO Capital Markets | Outperform |
| 2023-07-31 | Iniziato | Guggenheim | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2022-11-14 | Iniziato | Goldman | Neutral |
| 2022-11-14 | Iniziato | JP Morgan | Overweight |
| 2022-11-14 | Iniziato | Jefferies | Buy |
| 2022-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prime Medicine Inc Borsa (PRME) Ultime notizie
Order Flow Trends Show Accumulation in Prime Medicine Inc.Market Trend Review & Weekly Breakout Watchlists - classian.co.kr
Prime Medicine Insiders' Buying Signals Positive Trends - AInvest
Prime Medicine Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 Fed Impact & Precise Swing Trade Alerts - classian.co.kr
Reversal Confirmed Prime Medicine Inc. Stock Rallies Above MAMarket Performance Report & Community Consensus Stock Picks - classian.co.kr
Prime Medicine announces public stock offering; shares down 11.5% - MSN
How Prime Medicine Inc. stock performs during market volatilityMarket Movers & Daily Momentum Trading Reports - sundaytimes.kr
Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid promising tech - Investing.com
RSI Suggests Rebound May Be Near in Prime Medicine Inc.Bond Market & Expert Approved Momentum Ideas - beatles.ru
Prime Medicine, Inc. shares rise 2.10% premarket after positive market sentiment. - AInvest
Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Behind the Move? - AInvest
Guggenheim cuts Prime Medicine stock price target to $5 from $18 - Investing.com Canada
Does Prime Medicine Inc. stock reflect fundamentalsJuly 2025 Earnings & Expert Curated Trade Ideas - thegnnews.com
Is Prime Medicine Inc. exposed to political riskUltra High Profit Potential - newsyoung.net
Prime Healthcare Services Receives Universal Credit Rating Upgrades from Fitch, Moody's and S&P - AInvest
Is Prime Medicine Inc. forming higher highs and higher lowsMulti-Bagger Picks in Progress - thegnnews.com
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating - 富途牛牛
Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00 - Defense World
What makes Prime Medicine Inc. stock price move sharplyHigh Return Trade Roadmap with Setup Filters - Newser
Prime Medicine Inc. stock trendline breakdownFree Consistent Income Focused Trade List - Newser
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
How high can Prime Medicine Inc. stock goFree Community Verified Stock Suggestions - Newser
Prime Medicine stock price target lowered to $10 at Chardan on cash update - Investing.com Canada
Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position - TipRanks
Prime Medicine Inc. stock retracement – recovery analysisFree Stock Market Entry Timing Signals - Newser
Prime Medicine Reports Q2 2025 Results and Strategic Updates - TipRanks
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
PRME Revenue Misses by 73% - AOL.com
Prime Medicine reports Q2 EPS (41c), consensus (34c) - TipRanks
Prime Medicine, Inc. SEC 10-Q Report - TradingView
Prime Medicine, Inc. Q2 operating expenses USD 54.492 million - MarketScreener
Alphabet Discloses $4.95 Million Equity Purchase in Prime Medicine via GV - TechGraph
Major Investment Alert: Prime Medicine, Inc. Sees Significant Share Purchase! - TipRanks
Prime Medicine (NYSE:PRME) Shares Gap Up Following Insider Buying Activity - Defense World
Why Prime Medicine Inc. stock attracts strong analyst attentionPrice Action Summary and Entry Strategy Guide - Newser
Prime Medicine Holds Special Stockholder Meeting - TipRanks
Bank of New York Mellon Corp Acquires 26,478 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Head to Head Comparison: Prime Medicine (NYSE:PRME) vs. Calidi Biotherapeutics (NYSE:CLDI) - Defense World
Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity - Defense World
Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering - Wilson Sonsini
Prime Medicine Surges 8.5% Amid KDJ Golden Cross Signal and Biotech Sector Rally - AInvest
Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Driving the Move? - AInvest
Why is Prime Medicine Inc. stock attracting strong analyst attentionAchieve rapid capital gains with smart investing - Jammu Links News
What are the latest earnings results for Prime Medicine Inc.Free Consultation - Jammu Links News
What institutional investors are buying Prime Medicine Inc. stockGet insider insights into market trends - Jammu Links News
What drives Prime Medicine Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What are Prime Medicine Inc. company’s key revenue driversAchieve breakthrough performance in the market - Jammu Links News
When is Prime Medicine Inc. stock expected to show significant growthUnlock your portfolio’s hidden potential - Jammu Links News
What analysts say about Prime Medicine Inc. stockStay informed with daily expert analysis - Jammu Links News
Is Prime Medicine Inc. a growth stock or a value stockInvest confidently with advanced analysis tools - Jammu Links News
What is the risk reward ratio of investing in Prime Medicine Inc. stockUnlock powerful market trend analysis - Jammu Links News
Is Prime Medicine Inc. stock overvalued or undervaluedInvest smarter with daily market updates - Jammu Links News
Prime Medicine Inc Azioni (PRME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prime Medicine Inc Azioni (PRME) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):